BioIVT 'better positioned' to support ADME-Tox clients with Optivia purchase

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Alexander Traksel)
(Image: Getty/Alexander Traksel)

Related tags: Drug safety, Toxicology, ADME, Fda, Ema, Assay

BioIVT adds transporter assay products and services to its ADME-Toxicology portfolio with the acquisition of Optivia Biotechnology – a deal which aligns with the company’s efforts to support drug safety and efficacy, says VP.

BioIVT provides research models and services for drug discovery and development. The company, formerly BioreclamationIVT, today announced its acquisition of Santa Clara, CA-based Optivia Biotechnology, which provides transporter assay services.

Following the acquisition – financial terms of which were not disclosed – BioIVT’s portfolio now includes Optivaia’s entire product offering, including transporter assays, multi-transporter models, transporter systems biology, and molecular transport research solutions.

Optivia will join BioIVT’s Phasezero Research Services group and work closely with the company’s services division, which originated following BioIVT’s acquisition of Qualyst Transporter Solutions in 2017​.

Dr. Courtney Noah, BioIVT vice president, marketing, said the acquisition aligns with BioIVT’s efforts to support drug safety and efficacy by providing model systems “that enable a better understanding of complex drug transport processes.”

BioIVT now “will be better positioned”​ to support ADME (absorption, distribution, metabolism, and excretion) and toxicology clients through offerings such as IND (investigational new drug) enabling studies, high throughput screening platforms, and integrated transporter solutions, Noah explained.

“The Optivia suite of products and services allows for on-demand generation of hepatic models to look at one or many transporter mechanisms,”​ she said.

Drug-drug interaction

Playing a key role in drug uptake and disposition, transporter effects are evaluated during the lead candidate selection and optimization process.

As part of this, the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and Japanese Pharmaceuticals and Medical Devices Agency (PMDA) request that in vitro​ studies be conducted on nine specific transporters for drug-drug interaction (DDI) assessment and drug labeling.

The US FDA currently is establishing​ a public docket to aid its development of a policy/guidance document on the assessment of DDIs for therapeutic proteins.

Public comment should be submitted by today, July 9, 2018.

Related news

Show more

Related products

show more

Q&A: Effective Drug Product Process Development

Q&A: Effective Drug Product Process Development

Catalent Pharma Solutions | 14-Jan-2021 | Insight Guide

In this Q&A, a Catalent Biologics expert shares his expertise with drug product process development challenges, risks and how to mitigate them, the...

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

Related suppliers

Follow us


View more